1. Scrip
  2. >>Conferences
  3. >>ASCO

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

ASCO Offers Stage For New Data For CAR-T And ADC Candidates

 
• By Mandy Jackson

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

Long red ladder to goal target the business concept on blue pastel color background with shadows 3D rendering
New data support multiple candidates aimed at the target • Source: Shutterstock

GlaxoSmithKline PLC may win the race to bring a BCMA-targeting treatment for multiple myeloma to the market this year, but CAR-T therapies from Bristol-Myers Squibb Co./bluebird bio Inc. and Janssen Pharmaceutical Cos./Legend Biotech Corp. are close behind. While all three are effective in heavily pre-treated patients, the companies developing them are pursuing combination regimens and moving into earlier stages of the disease to raise the bar in myeloma treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences